JAZZ · Company research
1 upcoming catalysts · 0 phase 2+ trials on file
View Stock opens Yahoo Finance. Prices and performance charts are provided there.
Jazz expects to report results from its Phase 3 study of Modeyso (dordaviprone) for Recurrent H3 K27M-mutant diffuse glioma in the first half of 2027 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
The FDA’s decision on Jazz’s Ziihera (zanidatamab-hrii) for First-line HER2-positive locally advanced/metastatic gastroesophageal adenocarcinoma (combinations) was due on Aug 25, 2026. The outcome isn’t recorded here yet — the linked source has the latest.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Jazz reported results from its Phase 3 study of Ziihera (zanidatamab-hrii) for First-line HER2+ gastroesophageal adenocarcinoma in Q3 2026 (Jul–Sep). The linked source has what the numbers showed.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Zepzelca labeling supplement to remove 2L ES-SCLC indication submitted to FDA, in Q3 2026 (Jul–Sep). A company milestone for Jazz (Zepzelca (lurbinectedin) for ES-SCLC second-line): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Jazz presented data on Xywav (calcium, magnesium, potassium, and sodium oxybates) for Narcolepsy and idiopathic hypersomnia at a medical meeting on Jun 16, 2026. The linked source has the details.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Jazz reported results from its Phase 3 study of Zepzelca (lurbinectedin) for Relapsed (2L) metastatic small cell lung cancer on Jun 12, 2026. The study missed its main goal.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Jazz presented data on Ziihera (zanidatamab-hrii) for 1L HER2+ locally advanced or metastatic GEA at a medical meeting on May 27, 2026. The linked source has the details.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
FDA accepts Ziihera 1L GEA sBLA with priority review; PDUFA Aug 25, 2026, on Apr 27, 2026. A company milestone for Jazz (Ziihera (zanidatamab-hrii) for 1L HER2+ locally advanced or metastatic GEA): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page
Explore reported politician transactions and public investor statements connected to JAZZ.
View source-linked activity ↗No phase 2+ trials cached for this company.
No recent headlines on file.